Reviewing PDS Biotechnology (NASDAQ:PDSB) & Immunome (NASDAQ:IMNM)

PDS Biotechnology (NASDAQ:PDSB) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares PDS Biotechnology and Immunome”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50 million	($0.75)	-1.30
Immunome	$6.94 million	374.35	-$212.39 million	($2.42)	-9.48

PDS Biotechnology has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

PDS Biotechnology has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Immunome has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500.

Profitability

This table compares PDS Biotechnology and Immunome’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-241.95%	-90.36%
Immunome	N/A	-57.61%	-52.39%

Analyst Recommendations

This is a summary of current ratings for PDS Biotechnology and Immunome, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1	0	2	0	2.33
Immunome	1	0	10	0	2.82

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 824.97%. Immunome has a consensus target price of $33.45, suggesting a potential upside of 45.83%. Given PDS Biotechnology’s higher possible upside, equities analysts plainly believe PDS Biotechnology is more favorable than Immunome.

Insider & Institutional Ownership

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 7.7% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Immunome beats PDS Biotechnology on 7 of the 12 factors compared between the two stocks.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

About Immunome

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.